Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e145-50. doi: 10.1016/j.clml.2014.03.002. Epub 2014 Jun 11.
No abstract available

Keywords: Chemotherapy; Epstein-Barr virus-encoded small RNA-negative; Human immunodeficiency virus-negative; Interphase fluorescence in situ hybridization; Non-hodgkin lymphoma.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow / pathology
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Duodenum / pathology
  • Epirubicin / administration & dosage
  • Fatal Outcome
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / diagnostic imaging
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Middle Aged
  • Prednisone / administration & dosage
  • Pyrazines / administration & dosage
  • Remission Induction
  • Stomach / pathology
  • Thalidomide / administration & dosage
  • Tomography, X-Ray Computed
  • Vincristine / administration & dosage

Substances

  • Boronic Acids
  • Pyrazines
  • Epirubicin
  • Thalidomide
  • Vincristine
  • Bortezomib
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol